

UTILIZATION MANAGEMENT MEDICAL POLICY

POLICY: Oncology (Injectable – Antibody-Drug Conjugate – c-Met) – Emrelis Utilization Management Medical Policy

- Emrelis® (telisotuzumab vedotin-tllv intravenous infusion – AbbVie)

REVIEW DATE: 04/22/2026

OVERVIEW

Emrelis, a c-Met-directed antibody and microtubule inhibitor conjugate, is indicated for the following use:¹

- **Non-small cell lung cancer (NSCLC)**, in locally advanced or metastatic non-squamous disease with high c-Met protein overexpression ($\geq 50\%$ of tumor cells with strong [3+] staining), as determined by an FDA-approved test in adults who have received prior systemic therapy.

Guidelines

The National Comprehensive Cancer Network (NCCN) NSCLC guidelines (version 5.2026 – March 13, 2026) recommend Emrelis as one of the “Other Recommended” regimens for subsequent therapy treatment of adenocarcinoma, large cell, and NSCLC not otherwise specified (category 2A), regardless of prior immunotherapy use.² Emrelis is specifically recommended for c-Met/MET $\geq 50\%$ immunohistochemistry 3+ staining, and *EGFR* wild-type disease. Emrelis is also recommended for disease progression in this setting (category 2A). The guidelines mention in a footnote that testing for c-MET/MET immunohistochemistry is recommended at some point during progression. Timing of testing should be balanced with tissue conservation. Other recommended therapies in this setting, not specific for c-Met overexpression, include docetaxel, pemetrexed, gemcitabine, docetaxel + Cyramza® (ramucirumab intravenous injection), albumin-bound paclitaxel, and Enhertu® (fam-trastuzumab deruxtecan-nxki intravenous infusion) for human epidermal growth factor receptor (HER)2 overexpression.

POLICY STATEMENT

Prior Authorization is recommended for medical benefit coverage of Emrelis. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indication. Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below. Because of specialized skills required for evaluation and diagnosis of patients treated with Emrelis as well as the monitoring required for adverse events and long-term efficacy, approval requires Emrelis to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Emrelis is recommended in those who meet the following criteria:

FDA-Approved Indication

1. Non-Small Cell Lung Cancer. Approve for 1 year if the patient meets ALL of the following (A, B, C, D, E, and F):

- A) Patient is ≥ 18 years of age; AND
- B) Patient has locally advanced or metastatic, non-squamous disease; AND
- C) The tumor is epidermal growth factor receptor (*EGFR*) wildtype; AND
- D) The tumor has high c-Met protein overexpression, defined as a $\geq 50\%$ of tumor cells with strong [3+] staining; AND
- E) Patient has received at least one prior systemic therapy; AND
Note: Examples are cisplatin, carboplatin, pemetrexed, Keytruda (pembrolizumab intravenous infusion), Tecentriq (atezolizumab intravenous infusion), Opdivo (nivolumab intravenous infusion), Imfinzi (durvalumab intravenous infusion), Libtayo (cemiplimab-rwlc intravenous infusion).
- F) The medication is prescribed by or in consultation with an oncologist.

Dosing. Approve if each dose does not exceed 1.9 mg/kg (up to a maximum of 190 mg for patients ≥ 100 kg), administered as an intravenous infusion not more frequently than once every 2 weeks.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Emrelis is not recommended in the following situations:

- 1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

- 1. Emrelis™ intravenous infusion [prescribing information]. North Chicago, IL: AbbVie; May 2025.
- 2. The NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (version 5.2026 – March 13, 2026). © 2026 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on April 16, 2026.

HISTORY

Type of Revision	Summary of Changes	Review Date
New Policy	--	05/21/2025
Selected Revision	Non-Small Cell Lung Cancer: Added criterion the tumor is epidermal growth factor receptor (EGFR) wildtype.	06/11/2025
Annual Revision	Non-Small Cell Lung Cancer: With reference to high c-Met protein overexpression in the tumor, the requirement that it was “determined by an approved test” was removed.	04/22/2026